Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Cellectar Biosciences announced the publication of Phase 1 results for iopofosine I 131 in relapsed/refractory multiple myeloma within the peer-reviewed journal Cancers. The study of 31 heavily pretreated patients reported a manageable safety profile with primarily reversible hematologic toxicities and an overall response rate of 15.4%, with 84.6% of evaluable patients achieving stable disease or better.
Key figures
- Drug Name
- Iopofosine I 131
- Phase Of Trial
- Phase 1
- Mtd
- 31.25 mCi/m²
- Patient count
- 31
- Partial responses
- 4
- Overall response rate
- 15.4%
- Phase2 recommended dose
- 15 mCi/m²
- Efficacy evaluable patients
- 26
- Stable disease or better rate
- 84.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.